Travere Therapeutics (TVTX)
(Delayed Data from NSDQ)
$5.26 USD
-0.13 (-2.41%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $5.25 -0.01 (-0.19%) 7:58 PM ET
5-Strong Sell of 5 5
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TVTX 5.26 -0.13(-2.41%)
Will TVTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TVTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TVTX
Travere (TVTX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
TVTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Travere (TVTX) Stock Up More Than 30% in 3 Months: Here's Why
Wall Street Analysts Think Travere (TVTX) Could Surge 66.29%: Read This Before Placing a Bet
Mirum (MIRM) Down on Failure of Mid-Stage Study on Livmarli
Other News for TVTX
Travere Therapeutics (TVTX) Receives a Hold from Piper Sandler
Buy Rating Affirmed for Travere Therapeutics Following Filspari’s European Approval and Promising US Prospects
Buy Rating Affirmed for Travere Therapeutics on EU Approval and Promising Revenue Projections
Analysts Conflicted on These Healthcare Names: Travere Therapeutics (TVTX), Humana (HUM) and Merck & Company (MRK)
FILSPARI’s European Approval and Market Potential Bolster Buy Rating for Travere Therapeutics